Details for New Drug Application (NDA): 021920
✉ Email this page to a colleague
NDA 021920 describes NAPROXEN SODIUM, which is a drug marketed by Bionpharma, Catalent, Onesource Specialty, Patheon Softgels, Puracap Pharm Llc, Actavis Labs Fl Inc, Able, Adaptis, Amneal Pharms Ny, Aurobindo Pharma Ltd, Contract Pharmacal, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Granules India, Hamilton Pharms, Hetero Labs Ltd V, Hikma, Ivax Sub Teva Pharms, Lnk Intl Inc, Marksans Pharma, Novelgenix Theraps, Perrigo, Pharmobedient, Pld Acquisitions Llc, Pliva, Purepac Pharm, Roxane, Sandoz, Sciegen Pharms Inc, Sun Pharm Inds Ltd, Teva, Teva Pharms, Watson Labs, Yichang Humanwell, Amneal Pharms Co, Corepharma, Granules, P And L, Perrigo R And D, and Aurobindo Pharma, and is included in forty-eight NDAs. It is available from one hundred and twenty suppliers. There are five patents protecting this drug and one Paragraph IV challenge. Additional details are available on the NAPROXEN SODIUM profile page.
The generic ingredient in NAPROXEN SODIUM is naproxen sodium; pseudoephedrine hydrochloride. There are forty-two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the naproxen sodium; pseudoephedrine hydrochloride profile page.
The generic ingredient in NAPROXEN SODIUM is naproxen sodium; pseudoephedrine hydrochloride. There are forty-two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the naproxen sodium; pseudoephedrine hydrochloride profile page.
Summary for 021920
| Tradename: | NAPROXEN SODIUM |
| Applicant: | Bionpharma |
| Ingredient: | naproxen sodium |
| Patents: | 5 |
Pharmacology for NDA: 021920
| Mechanism of Action | Cyclooxygenase Inhibitors |
Suppliers and Packaging for NDA: 021920
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NAPROXEN SODIUM | naproxen sodium | CAPSULE;ORAL | 021920 | NDA | Bayer HealthCare LLC. | 0280-6080 | 0280-6080-01 | 1 BOTTLE in 1 CARTON (0280-6080-01) / 120 CAPSULE, LIQUID FILLED in 1 BOTTLE |
| NAPROXEN SODIUM | naproxen sodium | CAPSULE;ORAL | 021920 | NDA | Bayer HealthCare LLC. | 0280-6080 | 0280-6080-02 | 2 BOTTLE in 1 PACKAGE, COMBINATION (0280-6080-02) / 80 CAPSULE, LIQUID FILLED in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | OTC | Dosage: | CAPSULE;ORAL | Strength | EQ 200MG BASE | ||||
| Approval Date: | Feb 17, 2006 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Mar 3, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TEMPORARY REDUCTION OF FEVER | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Mar 3, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TEMPORARY RELIEF OF MINOR ACHES AND PAINS | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Mar 3, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TEMPORARY REDUCTION OF FEVER | ||||||||
Complete Access Available with Subscription
